FIELD: medicine; neurology; pharmacology.
SUBSTANCE: invention is intended for the treatment of depression. Patulithrin is used as an antidepressant.
EFFECT: invention makes it possible to increase the effectiveness of the therapeutic effect and exclude the occurrence of side effects.
1 cl, 1 dwg, 4 ex
Title | Year | Author | Number |
---|---|---|---|
USE OF OREGANOL A WITH NEUROTROPIC ACTIVITY | 2022 |
|
RU2802871C1 |
USE OF GAULTERIN AS ANTIDEPRESSANT | 2023 |
|
RU2825385C1 |
USE OF SALICIN HAVING NEUROTROPIC ACTIVITY | 2023 |
|
RU2832938C1 |
USE OF ISORHAMNETIN 3-O-β-D-GLUCOPYRANOSIDE, HAVING NEUROTROPIC ACTIVITY | 2024 |
|
RU2833215C1 |
USE OF CYNAROSIDE HAVING NEUROTROPIC ACTIVITY | 2023 |
|
RU2832839C1 |
USE OF APIGENIN HAVING NEUROTROPIC ACTIVITY | 2023 |
|
RU2832841C1 |
USE OF COSMOSIIN HAVING NEUROTROPIC ACTIVITY | 2023 |
|
RU2833214C1 |
USE OF PATULITRIN AS A DIURETIC | 2022 |
|
RU2807938C1 |
USE OF QUERCETIN AS A DIURETIC, SALURETIC AND CREATININURETIC AGENT | 2022 |
|
RU2802833C1 |
ANTIDEPRESSANT FOR CORRECTION OF SIDE EFFECTS FROM NEUROLEPTICS | 2019 |
|
RU2746012C2 |
Authors
Dates
2023-09-05—Published
2022-11-20—Filed